MAPT and Alzheimer disease: Blood-based biomarkers (BBBMs), including the Aβ1-42/1-40 ratio and phosphorylated tau181 (pTau181), have demonstrated significant diagnostic value in AD as indicators of underlying tau and amyloid pathology [2–6].